CN101014338B - 作为巨噬细胞弹性蛋白酶抑制剂的5-[3-(4-苄氧基苯基硫代)-呋喃-2-基]-咪唑烷-2,4-二酮和类似物 - Google Patents

作为巨噬细胞弹性蛋白酶抑制剂的5-[3-(4-苄氧基苯基硫代)-呋喃-2-基]-咪唑烷-2,4-二酮和类似物 Download PDF

Info

Publication number
CN101014338B
CN101014338B CN2005800285556A CN200580028555A CN101014338B CN 101014338 B CN101014338 B CN 101014338B CN 2005800285556 A CN2005800285556 A CN 2005800285556A CN 200580028555 A CN200580028555 A CN 200580028555A CN 101014338 B CN101014338 B CN 101014338B
Authority
CN
China
Prior art keywords
mmp
furan
methoxyphenyl
dione
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800285556A
Other languages
English (en)
Chinese (zh)
Other versions
CN101014338A (zh
Inventor
杨福德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yat Biological Polytron Technologies Inc
Original Assignee
QPS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QPS LLC filed Critical QPS LLC
Publication of CN101014338A publication Critical patent/CN101014338A/zh
Application granted granted Critical
Publication of CN101014338B publication Critical patent/CN101014338B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2005800285556A 2004-08-19 2005-08-17 作为巨噬细胞弹性蛋白酶抑制剂的5-[3-(4-苄氧基苯基硫代)-呋喃-2-基]-咪唑烷-2,4-二酮和类似物 Expired - Fee Related CN101014338B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60273604P 2004-08-19 2004-08-19
US60/602,736 2004-08-19
PCT/US2005/029259 WO2006023562A2 (en) 2004-08-19 2005-08-17 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase

Publications (2)

Publication Number Publication Date
CN101014338A CN101014338A (zh) 2007-08-08
CN101014338B true CN101014338B (zh) 2010-06-16

Family

ID=35968136

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800285556A Expired - Fee Related CN101014338B (zh) 2004-08-19 2005-08-17 作为巨噬细胞弹性蛋白酶抑制剂的5-[3-(4-苄氧基苯基硫代)-呋喃-2-基]-咪唑烷-2,4-二酮和类似物

Country Status (16)

Country Link
US (1) US7179831B2 (enExample)
EP (1) EP1789036B1 (enExample)
JP (1) JP5042833B2 (enExample)
KR (1) KR101197325B1 (enExample)
CN (1) CN101014338B (enExample)
AT (1) ATE508744T1 (enExample)
AU (1) AU2005277432B2 (enExample)
BR (1) BRPI0514470B8 (enExample)
CA (1) CA2577430C (enExample)
DK (1) DK1789036T3 (enExample)
ES (1) ES2364068T3 (enExample)
MX (1) MX2007001940A (enExample)
NZ (1) NZ553258A (enExample)
RU (1) RU2391339C2 (enExample)
SI (1) SI1789036T1 (enExample)
WO (1) WO2006023562A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051260A1 (en) * 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
ES2910833T3 (es) * 2016-08-19 2022-05-13 Foresee Pharmaceuticals Co Ltd Composición farmacéutica y procedimientos de usos
ES2865854T3 (es) * 2016-09-23 2021-10-18 Kaken Pharma Co Ltd Método para producir (r)-5-(3,4-difluorofenil)-5-[(3-metil-2-oxopiridin-1(2h)-il)metil]imidazolidin-2,4-diona y un producto intermedio para producir la misma
FI3793992T3 (fi) 2018-05-15 2024-04-17 Foresee Pharmaceuticals Usa Inc Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä
DK4058437T3 (da) * 2019-11-14 2025-01-20 Foresee Pharmaceuticals Usa Inc Matrix-metalloproteinase-(MMP)-inhibitorer og fremgangsmåder til anvendelse heraf
AU2022290589A1 (en) * 2021-06-08 2023-11-23 Foresee Pharmaceuticals Usa, Inc. Safe administration of mmp-12 inhibitor
RU2766551C1 (ru) * 2021-07-19 2022-03-15 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1509273A (zh) * 2001-03-15 2004-06-30 金属蛋白酶抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040577A1 (en) 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6352976B1 (en) * 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
RU2150469C1 (ru) * 1999-06-01 2000-06-10 Уфимский государственный нефтяной технический университет Способ получения 2-(фурил-2)-1,3-имидазолидинов
EP1288199A4 (en) 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US7041693B2 (en) * 2002-10-04 2006-05-09 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1509273A (zh) * 2001-03-15 2004-06-30 金属蛋白酶抑制剂

Also Published As

Publication number Publication date
CA2577430A1 (en) 2006-03-02
SI1789036T1 (sl) 2011-09-30
WO2006023562B1 (en) 2006-06-22
RU2391339C2 (ru) 2010-06-10
HK1107774A1 (en) 2008-04-18
DK1789036T3 (da) 2011-06-27
RU2007105822A (ru) 2008-09-27
BRPI0514470B1 (pt) 2021-01-05
JP5042833B2 (ja) 2012-10-03
KR20070045330A (ko) 2007-05-02
CN101014338A (zh) 2007-08-08
NZ553258A (en) 2011-02-25
EP1789036B1 (en) 2011-05-11
MX2007001940A (es) 2007-07-24
BRPI0514470A (pt) 2008-06-10
KR101197325B1 (ko) 2012-11-05
ATE508744T1 (de) 2011-05-15
WO2006023562A3 (en) 2006-04-20
WO2006023562A2 (en) 2006-03-02
EP1789036A2 (en) 2007-05-30
BRPI0514470B8 (pt) 2021-07-20
AU2005277432B2 (en) 2011-11-24
US7179831B2 (en) 2007-02-20
CA2577430C (en) 2010-12-07
ES2364068T3 (es) 2011-08-24
JP2008510701A (ja) 2008-04-10
EP1789036A4 (en) 2008-08-27
US20060041000A1 (en) 2006-02-23
AU2005277432A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
CN114573575B (zh) 一类含氧五元杂环化合物、合成方法、药物组合物及用途
KR101088247B1 (ko) 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
WO1998009949A1 (en) Novel acetamide derivatives and protease inhibitors
CN101014338B (zh) 作为巨噬细胞弹性蛋白酶抑制剂的5-[3-(4-苄氧基苯基硫代)-呋喃-2-基]-咪唑烷-2,4-二酮和类似物
KR20160075827A (ko) 플루오로페닐 피라졸 화합물
EP1615629B1 (en) Peptide deformylase inhibitors
EP4404931B1 (en) Azolo compounds for treatment of fibrotic diseases
HK1107774B (en) 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues useful as inhibitors of macrophage elastase
JP2003104984A (ja) 置換アミノピリミジニルアセトアミド誘導体の製造法
JP2002161036A (ja) ホスホジエステラーゼ阻害剤
UA81271C2 (en) 2-pyridone derivatives as inhibitors of neutrophile elastase, process for the preparation thereof and pharmaceutical composition based thereon

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1107774

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1107774

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20151008

Address after: Taipei City, Taiwan, China

Patentee after: Yat biological Polytron Technologies Inc

Address before: Delaware

Patentee before: Quest Pharmaceutical Services

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100616

Termination date: 20200817